Company intelligence / Profile preview

Dream Pharma

Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

Dream Pharma was a prominent South Korean pharmaceutical company primarily focused on the development and commercialization of treatments for obesity and metabolic disorders. The company established a leading position in the Korean weight loss market with a portfolio of anti-obesity medications and nutritional supplements. In 2014, Dream Pharma was acquired by the global pharmaceutical firm Alvogen for approximately $187 million, a move intended to strengthen Alvogen's presence in the Asia-Pacific region. Following the acquisition, Dream Pharma's operations were integrated into Alvogen Korea, where its legacy products continue to be marketed.

Therapeutic areas: Metabolic DisordersEndocrinology
Modalities: Small molecule
Industry: Biotech

Partnerships

Hanwha Chemical

Beyond the preview

Go deeper on Dream Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dream Pharma.

Explore the full profile